Assessment of concurrent neoplasms and a paraneoplastic association in MOGAD

Assessment of concurrent neoplasms and a paraneoplastic association in MOGAD

Abstract Cases of myelin oligodendrocyte glycoprotein (MOG) antibody‐associated disease (MOGAD) co‐occurring with neoplasms have been reported. In this international, retrospective cohort study in South Korea and the USA, 16 of 445 (3.6%) patients with MOGAD had concurrent neoplasm within 2 years of...

Full description

Saved in:
Bibliographic Details
Main Authors: Young Nam Kwon, Nanthaya Tisavipat, Yong Guo, Stephanie B. Syc‐Mazurek, Ji Yeon Han, Jun‐Soon Kim, Kyomin Choi, Seong‐il Oh, Seok‐Jin Choi, Eunhee Sohn, Jeeyoung Oh, Seung Woo Kim, Ha Young Shin, Byung Chan Lim, Byoung Joon Kim, Kyung Seok Park, Jung‐Joon Sung, Se Hoon Kim, Sung‐Hye Park, Anastasia Zekeridou, Claudia F. Lucchinetti, Sean J. Pittock, John J. Chen, Eoin P. Flanagan, Sung‐Min Kim
Format: Article
Language:English
Published: Wiley 2025-04-01
Series:Annals of Clinical and Translational Neurology
Online Access:https://doi.org/10.1002/acn3.52301
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Cases of myelin oligodendrocyte glycoprotein (MOG) antibody‐associated disease (MOGAD) co‐occurring with neoplasms have been reported. In this international, retrospective cohort study in South Korea and the USA, 16 of 445 (3.6%) patients with MOGAD had concurrent neoplasm within 2 years of MOGAD onset, resulting in a standardized incidence ratio for neoplasm of 3.10 (95% confidence interval [CI], 1.77–4.81; P < 0.001) when compared to the age‐ and country‐adjusted incidence of neoplasm in the general population. However, none of the nine tumor tissues obtained demonstrated MOG immunostaining. The slightly increased frequency without immunohistopathological evidence suggest with true paraneoplastic MOGAD is extremely rare.
ISSN:2328-9503

Similar Items